Background
==========

Cardiac involvement is a leading cause of morbidity and premature mortality in patients with scleroderma. Identification of this offers the opportunity for earlier and more stratified therapeutic intervention. Published data on the prognostic significance of left and right ventricular impairment and myocardial fibrosis in this cohort are limited. The study objective was to determine the prevalence and prognostic significance of abnormalities on cardiovascular magnetic resonance (CMR) in patients with scleroderma who have breathlessness and/or other cardiac symptoms.

Methods
=======

This is a retrospective longitudinal study of 126 consecutive patients with confirmed scleroderma and cardiac symptoms, who had undergone CMR. Completed scans were available in 124 of these. All scans were performed at 1.5 Tesla (Siemens Sonata or Avanto). Thinned myocardium was defined as thickness \<4mm, right ventricular hypertrophy defined as thickness\>5mm. The presence of left ventricular (LV) or right ventricular (RV) dilatation was defined as an increase in indexed LV or RV volumes compared to previously published normal ranges. Late gadolinium enhancement (LGE) was defined as an area of clearly increased signal intensity confirmed on phase swapping. All scans were analysed by two independent operators. All cause mortality was determined from review of hospital records and the national summary care database. A Cox proportional hazards model was used to determine predictors of mortality (IBM SPSS 19, USA).

Results
=======

Demographic data and CMR findings are shown in Table [1](#T1){ref-type="table"}. Mean age was 55 (range 19 to 82) years, 45% were male and 81% had at least one cardiovascular abnormality on the scan. Significant LV dysfunction (ejection fraction\<45%) was evident in 12% of patients and reduction in RV ejection fraction in 20% of patients. Myocardial fibrosis by LGE was found in 21% of patients (Table [1](#T1){ref-type="table"}). The number of patients with 1, 2 or 3 cardiovascular abnormalities on CMR were 13%, 13% and 10% respectively. In total, 46% of the patients had 4 or more abnormalities. There were 21 deaths during the follow-up period. CMR predictors of mortality were LV ejection fraction\<45% (Hazard ratio \[HR\] 3.9, 95% confidence interval \[CI\] 1.52-9.84, P=0.004) and impaired RV ejection fraction (HR 2.6, 95%CI 1.04-6.38, P=0.04). The presence of LGE did not predict mortality (HR 1.05, 95%CI 0.34-3.16, P=0.94).

###### 

Demographic data and CMR characteristics of 124 patients with symptomatic scleroderma.

  Clinical and CMR characteristics                              Number (of n=124)   Percentage (%)
  ------------------------------------------------------------- ------------------- ----------------------
  Age                                                           55                  \-
  M:F                                                           56:70               45% male, 55% female
  Patients with at least one cardiac abnormality                100                 83
  Thinned LV myocardium                                         8                   5
  LV dilatation                                                 24                  19
  LV wall motion abnormality                                    40                  32
  LVH                                                           31                  25
  Raised LV mass index                                          23                  19
  Reduced LV long axis fx                                       37                  30
  LV EF\<45%                                                    15                  12
  RV dilatation                                                 30                  24
  Reduction in RV EF                                            25                  20
  RVH                                                           22                  22
  Reduced RV long axis function                                 22                  17
  Pericardial effusion                                          20                  16
  LA enlargement (\>moderate)                                   27                  22
  RA enlargement (\>moderate)                                   29                  23
  Dilated PA                                                    45                  36
  Increased signal on T2-STIR                                   1                   \<1%
  Late gadolinium enhancement                                   26                  21
  Patients with only 1 cardiovascular abnormality on CMR        16                  13
  Patients with 2 cardiovascular abnormalities on CMR           17                  13
  Patients with 4 or more cardiovascular abnormalities on CMR   57                  46

CMR= cardiac magnetic resonance, LV=left ventricle, RV=right ventricle, EF=ejection fraction, MI=mass index, LVH=left ventricular hypertrophy, LA=left atrium, RA right atrium, PA=pulmonary artery, T2-STIR=Short Tau Inversion Recovery.

Conclusions
===========

This is, to the best of our knowledge, the largest cohort of patients with scleroderma to have undergone CMR. In this selective cohort, cardiovascular abnormalities on CMR are detectable in the majority (81%) of patients with scleroderma and breathlessness and/or other cardiac symptoms. Significant LV dysfunction was the strongest CMR predictor of mortality. Presence of LGE did not predict mortality.

Funding
=======

NA
